Acute Dystonic Reaction Management with Diphenhydramine

EPS management requires balancing psychiatric treatment needs with side effect mitigation. Options include: reducing antipsychotic dose (with psychiatrist consultation), switching to second-generation antipsychotics (with metabolic trade-offs), using clozapine (effective but requiring intensive monitoring), adding anti-akathisia medications (propranolol, benzodiazepines), and adding anti-parkinson medications (amantadine, anticholinergics). The choice depends on symptom severity, psychiatric necessity, and individual patient factors.

5-HT2A receptor antagonism significantly influences extrapyramidal symptoms (EPS) and akathisia. Drugs with strong 5-HT2A antagonism (clozapine, risperidone) have lower rates of EPS and akathisia. The best balance comes from drugs combining 5-HT2A antagonism with 5-HT1A partial agonism (clozapine). Akathisia is often misdiagnosed as EPS and inappropriately treated with anticholinergics; instead, alpha-2 adrenergic agonists, benzodiazepines, beta-blockers, and trazodone are more effective. Akathisia is dose-related—prevention through conservative dosing is best. When patients appear stable mid-switch, continuing the cross-taper while maintaining or slightly increasing the second drug is recommended. The pace depends on the goal: rapid transition for efficacy issues, gradual for tolerability/safety issues. Distinguishing between tolerability (symptoms felt by patient) and safety (asymptomatic risks) is crucial. Tolerability issues require faster intervention; safety issues allow slower transitions.

When discontinuing psychiatric medications after long-term use, a microtapering approach (very gradual reductions) is often necessary due to the brain's adaptation to chronic medication presence. Making too large of a decrease too quickly can trigger severe withdrawal symptoms.

When switching antipsychotics, it is best practice to taper down the current dose while simultaneously adding the newer antipsychotic. Abrupt withdrawal should be avoided. If forced to choose between options, switching to a second-generation antipsychotic while tapering the first-generation agent is preferable to abrupt discontinuation.

Principles for antipsychotic medication selection: (1) Risperidone is first-line for new patients; (2) Haloperidol is reserved for patients who have responded well and tolerate it adequately; (3) Clozapine is second-line for treatment-resistant cases. Extrapyramidal side effects (EPS) include acute dystonia, akathisia, parkinsonism, and tardive dyskinesia. Management includes adjusting medication dosage, switching to medications with lower EPS risk, and adding anticholinergic medications. Long-term use of anticholinergics may cause cognitive decline. Medication adherence principles: (1) Patients should continue medication even when feeling better; (2) Treatment duration should be at least 2 years before considering dose reduction; (3) Complete discontinuation should only be attempted after 2-5 years of stable remission; (4) Approximately 25% of patients may successfully discontinue medication; (5) Approximately 50% require lifelong medication; (6) Approximately 25% have poor prognosis regardless of treatment.

Laryngospasm is a rare but serious side effect of ketamine where the vocal cords go into spasm and shut tightly, blocking the airway. This condition is extremely dangerous because it prevents breathing. Emergency management includes using an oxygen mask to push air through the tightened throat muscles and pressing on a point just behind the jaw (stimulating the vagus nerve) to help break the spasm. If laryngospasm persists despite these maneuvers, intubation may be necessary to secure the airway.

Laryngospasm is a life-threatening emergency during emergence, classified as partial or complete. Partial laryngospasm allows some airflow with audible stridor and responds to propofol (30-50 mg adult dose), positive pressure ventilation at 20 cm H2O, and anesthetic gas. Complete laryngospasm produces no airflow, identified by sternal notch depression and mask fogging, and carries higher pulmonary edema risk in muscular patients. Emergency drugs must always be within arm's reach, ideally pre-drawn. Stage II of anesthesia during emergence presents risks including laryngospasm, recognized by heart rate spikes, irregular respirations, breath-holding with stimulation, and pupillary deviation. Patients must demonstrate ability to respond to commands before extubation.

Neuroleptic Malignant Syndrome (NMS) is a serious but rare life-threatening emergency associated with antipsychotic treatment, more common with first-generation medications like haloperidol and chlorpromazine. Key features include extreme muscle rigidity (the 'M' of M&M) and mutism (the other 'M'), fever, and autonomic instability (rapid heart rate, blood pressure fluctuations, sweating). Laboratory findings include elevated creatine kinase (CPK) indicating muscle destruction, myoglobinuria (myoglobin in urine from muscle breakdown), and possibly elevated white blood cells and liver enzymes. Treatment requires immediate discontinuation of the antipsychotic, supportive care (hydration, temperature control), and pharmacological management with bromocryptine (a dopamine D2 agonist that counteracts dopamine blockade) and dantrolene (a skeletal muscle relaxant for muscle rigidity). A helpful mnemonic is 'Fever, Pneumonia, Elevated enzymes, Rigidity' (FPER).

Laryngospasm presents with characteristic ventilator graphics: no spontaneous breathing efforts, absent ETCO2 waveform (shark fin appearance), and high peak inspiratory pressure (often >40 cmH2O). The ventilator's safety mechanism (pressure limit alarm) prevents excessive pressure delivery, but default settings (typically 30-35 cmH2O) may not overcome severe laryngospasm. Management requires: increasing pressure limit setting to 60 cmH2O to overcome the spasm, administering bronchodilators, reducing tidal volume and I:E ratio once spasm resolves, and monitoring plateau pressure to ensure lung protection. The shark fin ETCO2 pattern is a key diagnostic clue.

Laryngospasm is a life-threatening complication occurring at or just after extubation, commonly caused by airway secretions irritating the larynx. Sevoflurane increases secretions and thus raises laryngospasm risk. Clinical signs include desaturation and crepitations on auscultation. Immediate treatment involves positive pressure ventilation to dislodge any mucus plug, followed by administration of a small dose of succinylcholine (suxamethonium) which relieves laryngospasm within 30 seconds. Failure to treat promptly can lead to negative pressure pulmonary edema, a serious complication requiring extended ICU care.

AIMS interpretation requires understanding limitations: it screens for TD but doesn't indicate illness severity—peroral TD can cause severe disability preventing outdoor activities. Up to 10-20% of drug-naive chronic psychotic patients have abnormal movements. TD significantly impacts quality of life with poor employability and marriage prospects; aware patients often develop depression, social phobia, and referential thinking. AIMS should be repeated at every clinical encounter due to waxing/waning course. Pre-medication assessment is essential. Follow-up protocols: first-generation antipsychotics require 6-month intervals; second-generation require annual assessments; geriatric cases need closer monitoring. Beyond serial AIMS, clinicians must ask about symptom fluctuation and impairment in daily activities including eating, drinking, speaking, dressing, writing, typing, computer work, leisure, and social situations to fully assess disability and guide treatment decisions.

The Abnormal Involuntary Movement Scale (AIMS) is a standardized clinical examination tool used to detect tardive dyskinesia and parkinsonism. It takes approximately 10 minutes to administer and involves observing the patient's movements while they sit, open their mouth, and extend their arms. The American Psychiatric Association recommends administering this test every 3-6 months to all patients taking antipsychotic medications. In some U.S. states, this has been made mandatory in psychiatric hospitals and clinics.

The Abnormal Involuntary Movement Scale (AIMS) is a 12-item clinical assessment tool developed in the 1970s to detect and monitor tardive dyskinesia, an involuntary movement disorder that can develop as a side effect of long-term antipsychotic medication use; the examination involves observing patients through various positions and movements (sitting, standing, walking, finger tapping) and rating each of the 12 body regions on a 5-point severity scale (0-4), with a positive result indicating scores of 2 or higher in two or more areas or 3-4 in a single area, requiring administration every 3-6 months for effective monitoring.

Antipsychotics treat psychosis by blocking dopamine release. Typical (old-generation) antipsychotics cause significant extrapyramidal side effects (EPS) including acute dystonia, akathisia, and tardive dyskinesia. Atypical (new-generation) antipsychotics cause fewer EPS but present cardiac risks. Monitoring includes the Abnormal Involuntary Movement Scale (AIMS) every three months, EKGs, CBCs, liver function tests, and weight/fasting glucose monitoring. Neuroleptic malignant syndrome is life-threatening requiring immediate medication discontinuation. Healthcare providers must distinguish medication side effects from actual behavioral issues, as people with intellectual disabilities rarely self-report EPS symptoms.

The Abnormal Involuntary Movement Scale (AIMS) rates movement abnormalities from 0-4, with higher scores indicating worse symptoms. It should be administered every 6 months for patients on antipsychotic medications to monitor for tardive dyskinesia.